Literature DB >> 10778729

Progressive disease in children with medulloblastoma/PNET during preradiation chemotherapy.

A Tornesello1, S Mastrangelo, D Piciacchia, V Bembo, C Colosimo, C Di Rocco, R Mastrangelo.   

Abstract

The overall prognosis in children with medulloblastoma/PNET has not significantly improved over the past decade. Intensive neoadjuvant chemotherapy has not yet adequately explored. We evaluated the short-term clinical results of an intensive chemotherapy regimen in high risk children with newly diagnosed MB/PNET, after surgery and before radiation. Twelve previously untreated patients with high-risk medulloblastoma/PNET, according to Chang's classification, were treated with the following chemotherapy regimen: high dose carboplatin 600 mg/m2/day on days 1 and 2; the same course was administered 4 weeks later. One month later, high dose cyclophosphamide 2 g/m2/day on days 1 and 2, followed by an identical course 4 weeks later. Vincristine 1, 5 mg/m2 i.v. was given on the first day of each course. Systemic evaluation of the disease included imaging of the entire neuraxis, including MRI of the entire spine. Out of 12 enrolled, 7 patients were able to be evaluated for a residual disease after surgery. After two cycles of high dose carboplatin, we noted 1 CR, 4 PR and 2 MR. After the subsequent two cycles of high dose cyclophosphamide we observed an additional response in 4 cases. On the other hand, 4 patients clearly showed evidence of PD immediately after the first course of cyclophosphamide (2 cases) or following the second course. Three of the 4 patients had shown respectively 1 CR and 2 PR after the second course of carboplatin. Whereas it was confirmed that 2 courses of high dose carboplatin is effective in high risk MB/PNET children, we observed an unacceptable number of PD during the subsequent high dose cyclophosphamide therapy. A review from the literature also suggests that, in general, the longer radiotherapy is delayed, the higher the incidence of PD. In the search for the optimal drug combination in "sandwich chemotherapy" for children with high risk MB/PNET, PD must be reduced to an acceptable incidence, since a high number of PD may significantly lower the probability of long-term survival.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10778729     DOI: 10.1023/a:1006133404936

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  24 in total

1.  Adjuvant chemotherapy for medulloblastoma: the first multi-centre control trial of the International Society of Paediatric Oncology (SIOP I).

Authors:  D M Tait; H Thornton-Jones; H J Bloom; J Lemerle; P Morris-Jones
Journal:  Eur J Cancer       Date:  1990-04       Impact factor: 9.162

2.  The treatment of medulloblastoma. Results of a prospective randomized trial of radiation therapy with and without CCNU, vincristine, and prednisone.

Authors:  A E Evans; R D Jenkin; R Sposto; J A Ortega; C B Wilson; W Wara; I J Ertel; S Kramer; C H Chang; S L Leikin
Journal:  J Neurosurg       Date:  1990-04       Impact factor: 5.115

Review 3.  Perspectives on investigational chemotherapy and biologic therapy for childhood brain tumors.

Authors:  R P Kadota
Journal:  J Pediatr Hematol Oncol       Date:  1996-02       Impact factor: 1.289

4.  Eight drugs in one day chemotherapy for brain tumors: experience in 107 children and rationale for preradiation chemotherapy.

Authors:  T W Pendergrass; J M Milstein; J R Geyer; A F Mulne; E J Kosnik; J D Morris; R L Heideman; F B Ruymann; J T Stuntz; W A Bleyer
Journal:  J Clin Oncol       Date:  1987-08       Impact factor: 44.544

5.  Brain tumours under the age of three. The price of survival. A retrospective study of 20 long-term survivors.

Authors:  E Suc; C Kalifa; R Brauner; J L Habrand; M J Terrier-Lacombe; G Vassal; J Lemerle
Journal:  Acta Neurochir (Wien)       Date:  1990       Impact factor: 2.216

6.  Brain tumors in children under 2 years: treatment, survival and long-term prognosis.

Authors:  B H Cohen; R J Packer; K R Siegel; L B Rorke; G D'Angio; L N Sutton; D A Bruce; L Schut
Journal:  Pediatr Neurosurg       Date:  1993 Jul-Aug       Impact factor: 1.162

7.  Preradiation chemotherapy for newly diagnosed childhood brain tumors. A modified Phase II trial.

Authors:  J C Allen; L Helson; B Jereb
Journal:  Cancer       Date:  1983-12-01       Impact factor: 6.860

8.  The treatment and long-term prognosis of children with intracranial tumors: a study of 610 cases, 1950-1981.

Authors:  H J Bloom; J Glees; J Bell; S E Ashley; C Gorman
Journal:  Int J Radiat Oncol Biol Phys       Date:  1990-04       Impact factor: 7.038

9.  High-dose cyclophosphamide chemotherapy for recurrent CNS tumors in children.

Authors:  J C Allen; L Helson
Journal:  J Neurosurg       Date:  1981-11       Impact factor: 5.115

10.  Preirradiation chemotherapy with carboplatin and etoposide in newly diagnosed embryonal pediatric CNS tumors.

Authors:  R L Heideman; E H Kovnar; S J Kellie; E C Douglass; A J Gajjar; A W Walter; J A Langston; J J Jenkins; Y Li; C Greenwald
Journal:  J Clin Oncol       Date:  1995-09       Impact factor: 44.544

View more
  1 in total

1.  Immunohistochemical markers for prognosis of average-risk pediatric medulloblastomas. The effect of apoptotic index, TrkC, and c-myc expression.

Authors:  Andrey Korshunov; Marina Savostikova; Sergey Ozerov
Journal:  J Neurooncol       Date:  2002-07       Impact factor: 4.130

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.